Evidence map›Paper›PMID 41634087›Full record

ArticleNPJ precision oncology2026

Generalisation of automatic tumour segmentation in histopathological whole-slide images across multiple cancer types.

Ole-Johan Skrede, Manohar Pradhan, Maria Xepapadakis Isaksen, Tarjei Sveinsgjerd Hveem, Ljiljana Vlatkovic, Arild Nesbakken, Kristina Lindemann, Gunnar B Kristensen, Jenneke Kasius, Alain G Zeimet and 13 more

Abstract read
In one paragraph

Article in NPJ precision oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Ole-Johan SkredeInstitute for Cancer Genetics and Informatics, Oslo University Hospital, Oslo, Norway. olejohas@ifi.uio.no.
Manohar PradhanInstitute for Cancer Genetics and Informatics, Oslo University Hospital, Oslo, Norway.
Maria Xepapadakis IsaksenInstitute for Cancer Genetics and Informatics, Oslo University Hospital, Oslo, Norway.
Tarjei Sveinsgjerd HveemInstitute for Cancer Genetics and Informatics, Oslo University Hospital, Oslo, Norway.
Ljiljana VlatkovicInstitute for Cancer Genetics and Informatics, Oslo University Hospital, Oslo, Norway.
Arild NesbakkenDepartment of Molecular Oncology, Oslo University Hospital, Oslo, Norway.
Kristina LindemannInstitute of Clinical Medicine, University of Oslo, Oslo, Norway.
Gunnar B KristensenInstitute for Cancer Genetics and Informatics, Oslo University Hospital, Oslo, Norway.
Jenneke KasiusDepartment of Gynecological Oncology, Centre for Gynecological Oncology Amsterdam, Amsterdam University Medical Centres, Amsterdam, The Netherlands.
Alain G ZeimetDepartment of Obstetrics and Gynaecology, Innsbruck Medical University, Innsbruck, Austria.
Odd Terje BrustugunInstitute of Clinical Medicine, University of Oslo, Oslo, Norway.
Lill-Tove Rasmussen BusundDepartment of Medical Biology, UiT The Arctic University of Norway, Tromsø, Norway.
Elin H RichardsenDepartment of Medical Biology, UiT The Arctic University of Norway, Tromsø, Norway.
Erik Skaaheim HaugInstitute for Cancer Genetics and Informatics, Oslo University Hospital, Oslo, Norway.
Bjørn BrennhovdDepartment of Urology, Oslo University Hospital, Oslo, Norway.
Emma RewcastleDepartment of Pathology, Stavanger University Hospital, Stavanger, Norway.
Melinda LillesandDepartment of Pathology, Stavanger University Hospital, Stavanger, Norway.
Vebjørn KvikstadDepartment of Forensic Medicine, Oslo University Hospital, Oslo, Norway.
Emiel JanssenDepartment of Pathology, Stavanger University Hospital, Stavanger, Norway.
David J KerrNuffield Division of Clinical Laboratory Sciences, University of Oxford, Oxford, UK.
Knut LiestølInstitute for Cancer Genetics and Informatics, Oslo University Hospital, Oslo, Norway.
Fritz AlbregtsenInstitute for Cancer Genetics and Informatics, Oslo University Hospital, Oslo, Norway.
Andreas KleppeInstitute for Cancer Genetics and Informatics, Oslo University Hospital, Oslo, Norway.

Funding

Norges Forskningsråd 259204
6 · The paper itself

Abstract

Deep learning is expected to aid pathologists in tasks such as tumour segmentation. We developed a general tumour segmentation model for histopathological images and examined its performance in different cancer types. The model was developed using over 20,000 whole-slide images from over 4000 patients with colorectal, endometrial, lung, or prostate carcinoma. Performance was validated in pre-planned analyses on external cohorts with over 3000 patients across six cancer types. Exploratory analyses included over 1500 additional patients from The Cancer Genome Atlas. Average Dice coefficient was over 80% in all validation cohorts with en bloc resection specimens and in The Cancer Genome Atlas cohorts. No performance loss was observed when comparing the general model with single-cancer models specialised in cancer types from the development set. In conclusion, extensive and rigorous evaluations demonstrate that generic tumour segmentation by a single model is possible across cancer types, patient populations, sample preparations and slide scanners.

Identifiers

PMID41634087
PMCPMC12976075

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.